Lurasidone is approved for schizophrenia and bipolar depression on the strength of acute trials that mostly reported a single number: the change in PANSS total score. A 2026 post-hoc analysis of the JEWEL Phase 3 trial pulls that number apart, looking separately at five symptom domains and at all 30 individual items of the PANSS …
Latuda (Lurasidone) is a relatively new atypical antipsychotic that was approved in 2013 for the treatment of schizophrenia and depressive episodes in Type 1 Bipolar disorder. Many have made the argument that since this is a “newer” antipsychotic, it’s likely to be “better” than the crop of older medications on the market. While no single …
Latuda (Lurasidone) is a new atypical antipsychotic drug that is approved for the treatment of depressive episodes in bipolar disorder (type 1) as well as schizophrenia. It is considered a relatively new drug as it was just approved in 2013 to treat depressive episodes for people with bipolar I disorder. This drug is somewhat unique …